Relevium Medical Ltd is developing novel gel-based treatments for painful joint disorders and having developed the first application of its kind to treat knee osteoarthritis for which there is currently no adequate treatment. With 560 million people worldwide suffering with the condition, Relevium is well positioned for its next phase of growth.